Search

97 Result(s)
Sort by

BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Supporting Fundappas

Supporting Fundappas

Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Reggie the Red Blood Cell

Reggie the Red Blood Cell

Join Reggie, our curious red blood cell, on a journey exploring connections between the heart, kidneys and pancreas.
2019 performance

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Innovation Prize Winners

Innovation Prize Winners

Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma